A Phase 2 clinical trial involving Melanotan II (MT-II) was listed as recruiting as of November 12, 2026. The study, registered as NCT07437560, is titled "Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo." It is evaluating MT-II as an adjunct to narrowband UVB phototherapy in people with stable nonsegmental vitiligo. The trial is currently in Phase 2 and is actively recruiting participants according to the registry listing. Melanotan II remains classified as an unapproved compound under research status, and this listing does not indicate any outcomes or efficacy data at this stage. No results have been posted for this trial as of the date reported. The registry entry provides only the trial's title, phase, and recruitment status at this time. Readers interested in background on this compound can consult the compound overview for additional context.
Melanotan II Phase 2 Trial for Vitiligo Repigmentation Now Recruiting
See the full melanotan ii overview
Source: https://clinicaltrials.gov/study/NCT07437560